The multi-ethnic global lung initiative 2012 (GLI-2012) norms reflect contemporary adult's Algerian spirometry.

Related Articles

The multi-ethnic global lung initiative 2012 (GLI-2012) norms reflect contemporary adult’s Algerian spirometry.

PLoS One. 2018;13(9):e0203023

Authors: Ketfi A, Gharnaout M, Bougrida M, Ben Saad H

BACKGROUND: The validation of the multi-ethnic GLI-2012 spirometric norms has been debated in several countries. However, its applicability in Algeria has not been verified.
AIM: To ascertain how well the GLI-2012 norms fit contemporary adult Algerian spirometric data.
METHODS: This was a cross-sectional study of a convenience sample of 300 healthy non-smoker adults (50% men, age range: 18-85 years) recruited from the Algiers region general population. All participants underwent a clinical examination and a plethysmography measurement. Z-scores for some spirometric data [FEV1, FVC, FEV1/FVC and forced expiratory flow at 25-75% of FVC (FEF25-75%)] were calculated. If the average Z-score deviated by “< ± 0.5” from the overall mean, the GLI-2012 norms would be considered as reflective of contemporary Algerian spirometry.
RESULTS: The means±SDs of age, height, weight, FVC, FEV1, FEV1/FVC and FEF25-75% of the participants were, respectively, 48±17 years, 1.65±0.10 m, 73±14 kg, 4.04±1.04 L, 3.18±0.82 L, 0.79±0.05 and 4.09±1.09 L/s. Almost the quarter of participants were obese. The total sample means±SDs Z-scores were 0.22±0.87 for FVC, 0.04±0.88 for FEV1, -0.34±0.67 for FEV1/FVC and 0.93±0.79 for FEF25-75%. For men and women, only the means±SDs of the FEF25-75% Z-scores exceeded the threshold of “± 0.5”, respectively, 1.13±0.77 and 0.73±0.76.
CONCLUSION: Results of the present study, performed in an Algerian population of healthy non-smoking adults, supported the applicability of the GLI-2012 norms to interpret FEV1, FVC and FEV1/FVC but not the FEF25-75%.

PMID: 30180191 [PubMed – in process]

Source link

Related posts

Idiopathic Pulmonary Arterial Hypertension Unmasked by Pregnancy.


Progress and challenges for new NHS priority conditions: Heart and circulatory diseases


Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy